In agreement with pharmacological inhibition, genetically engineered deletion of AT1a receptors strikingly reduced atherosclerosis in both apoE −/− and LDL receptor −/− mice in multiple studies [14]–[19]. This evidence concerns the gene LDLR and atherosclerosis.